Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies

Partners ONK Therapeutics To Develop Five Candidates

Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.

Intellia Therpeutics
Intellia is using its CRISPR technology for in vivo and ex vivo applications, the latter focused on next-gen cancer immunotherapies. • Source: Alamy

Intellia Therapeutics is to broaden its reach in oncology immunotherapy by combining its expertise in CRISPR gene-editing with allogeneic natural killer (NK) cell therapies being developed by ONK Therapeutics.

Intellia’s most eye-catching venture is groundbreaking in vivo gene-editing program NTLA-2001, which it could file later this year, but it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip